Pfizer's Pneumococcal Vaccine Shows Strong Immune Response in Trial

• Antibody levels after the third dose of 25vPnC were 8.8 times higher than Prevnar 20, increasing to 15 times higher after the fourth dose, with no safety concerns identified in the trial
• The vaccine could protect against approximately 90% of disease-causing pneumococcal strains in children under five, compared to current available shots
• Pfizer has begun a late-stage trial comparing 25vPnC with Prevnar 20 in up to 2,400 infants and plans to start clinical development of a 35-strain adult vaccine candidate by end of 2026

Summary: Pfizer's Pneumococcal Vaccine Shows Strong Immune Response in Trial

Key Development:

Pfizer announced on May 20 that its experimental 25-valent pneumococcal vaccine (25vPnC) demonstrated significantly superior immune response compared to its current vaccine, Prevnar 20, in a mid-stage trial involving healthy infants.

Critical Data Points:

• Antibody levels were 8.8 times higher after the third dose of 25vPnC versus Prevnar 20
• After the fourth dose, antibody levels reached 15 times higher than the current vaccine
• The new vaccine could potentially protect against approximately 90% of disease-causing strains in children under five years old
• A late-stage trial has been initiated with up to 2,400 infants to compare 25vPnC with Prevnar 20

Product Background:

Prevnar 20 received FDA approval in 2021 for adults and was expanded to infants and children in 2023. Pneumococcal disease causes infections affecting multiple body parts, including lungs, and carries elevated pneumonia risk.

Safety Profile:

The 25vPnC vaccine showed strong immune responses across all targeted strains, was well-tolerated, and presented no safety concerns during the trial.

Pipeline Development:

Pfizer is also advancing a 35-strain pneumococcal vaccine candidate for adults, with clinical development planned to begin by end of 2026.

Market Implications:

This advancement positions Pfizer to strengthen its leadership in the pneumococcal vaccine market, potentially capturing greater market share in pediatric vaccinations. The enhanced efficacy profile could drive substantial revenue growth, particularly given that children under 5 and adults over 50 represent high-risk populations according to the CDC.